1 August 2024 in Clinical Kidney Journal
Kidney transplantation is an effective way to improve the condition of patients with end-stage renal disease. However, maintaining long-term graft function and improving patient survival remain a key challenge after kidney transplantation. Dysbiosis of intestinal flora has been reported to be associated with complications in renal transplant recipients. The commensal microbiota plays an important role in the immunomodulation of the transplant recipient responses. However, several processes, such as the use of perioperative antibiotics and high-dose immunosuppressants in renal transplant recipients, can lead to gut dysbiosis and disrupt the interaction between the microbiota and the host immune responses, which in turn can lead to complications such as infection and rejection in organ recipients. In this review, we summarize and discuss the changes in intestinal flora and their influencing factors in patients after renal transplantation as well as the evidence related to the impact of intestinal dysbiosis on the prognosis of renal transplantation from in vivo and clinical studies, and conclude with a discussion of the use of microbial therapy in the transplant population. Hopefully, a deeper understanding of the function and composition of the microbiota in patients after renal transplantation may assist in the development of clinical strategies to restore a normal microbiota and facilitate the clinical management of grafts in the future.
23 July 2026 in Organ Medicine
Background: The recurrence of immunoglobulin A nephropathy (IgAN) after kidney transplantation (KT) is common and compromises long‐term graft survival; however, the early identification of patients at high risk of recurrence remains a clinical challenge. This study evaluated the roles of serum galactose‐deficient IgA1 (Gd‐IgA1), proliferation‐inducing ligand (APRIL), and B‐cell activating factor (BAFF) in predicting post‐transplant IgAN recurrence. Methods: This retrospective case–control study included patients with primary IgAN who underwent KT at the First Affiliated Hospital, Sun Yat‐sen University, from September 2014 to June 2023. Patients were divided into two groups: post‐transplantation IgAN recurrence ( n = 19) and non‐recurrence ( n = 25). Serum levels of Gd‐IgA1, APRIL, and BAFF were measured pre‐transplantation and at 3, 6, 12, 24, and 36 months post‐transplantation. Results: Recipients of kidneys from living donors had a significantly higher risk of IgAN recurrence compared with deceased‐donor recipients (odds ratio = 30.6, p = 0.001). Serum Gd‐IgA1 levels showed good discriminative ability for recurrence at 3 months (area under the curve: 0.85, 95% confidence interval: 0.72–0.99) and 6 months (area under the curve: 0.89, 95% confidence interval: 0.76–1.00) after transplantation. Elevated Gd‐IgA1 levels at 3 and 6 months were significantly associated with recurrence in univariate analyses, and remained the only independent predictor in multivariate Cox models. BAFF levels were significantly lower in the recurrence group at 12 months, while APRIL levels did not differ between the groups at any time point. Conclusions: Serum Gd‐IgA1 levels could effectively predict IgAN recurrence risk in patients post‐KT.